CEL-SCI and University of Georgia lab to work on COVID-19 drug

24 March 2020

Austro-American company CEL-SCI Corporation (NYSE American: CVM) and the University of Georgia’s (UGA) Center for Vaccines and Immunology have announced a collaboration in COVID-19.

CEL-SCI’s immunotherapy candidate, using ligand antigen epitope presentation system (LEAPS) platform technology, aims to treat patients at highest risk of dying from the virus.

The collaboration will begin with pre-clinical studies based on the experiments previously conducted with LEAPS immunotherapy in partnership with the National Institutes for Allergies and Infectious Diseases, against another respiratory virus, H1N1, involved in the 2009 H1N1 flu pandemic.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK